Abstract | AIM: METHODS: This review summarizes the current clinical evidence for the effectiveness and safety of subcutaneous insulin lispro injections in non-severe DKA patients. Relevant studies were identified by a systematic literature search through the PubMed database. RESULTS: To date, four small randomized studies (156 patients overall; three studies in adults and one in paediatric patients with diabetes) have directly compared subcutaneous insulin lispro injections every 1-2h vs continuous intravenous infusions of regular insulin. Patients with severe complications were excluded. In all studies, the mean time to resolution of DKA was similar in both treatment groups [range (three studies): lispro 10-14.8h; regular insulin 11-13.2h]. The mean time to resolution of hyperglycaemia, total insulin doses required, number of hospitalization days and number of hypoglycaemic episodes were similar in both treatment groups; no severe complications or DKA recurrences were reported, and one study showed a 39% cost reduction for the insulin lispro group. CONCLUSION:
|
Authors | M Vincent, E Nobécourt |
Journal | Diabetes & metabolism
(Diabetes Metab)
Vol. 39
Issue 4
Pg. 299-305
(Sep 2013)
ISSN: 1878-1780 [Electronic] France |
PMID | 23642642
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Copyright | Copyright © 2013. Published by Elsevier Masson SAS. |
Chemical References |
|
Topics |
- Adult
- Costs and Cost Analysis
- Diabetic Ketoacidosis
(drug therapy, economics, epidemiology)
- Health Resources
- Humans
- Hypoglycemia
(chemically induced, epidemiology)
- Injections, Subcutaneous
- Insulin Lispro
(administration & dosage, adverse effects, economics)
|